VENTOLIN I.V. INFUSION SOLUTION 5.0MG SALBUTAMOL IN 5ML (1000MCG/ML)

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

SALBUTAMOL (SALBUTAMOL SULFATE)

थमां उपलब्ध:

GLAXOSMITHKLINE INC

ए.टी.सी कोड:

R03CC02

INN (इंटरनेशनल नाम):

SALBUTAMOL

डोज़:

1MG

फार्मास्यूटिकल फॉर्म:

SOLUTION

रचना:

SALBUTAMOL (SALBUTAMOL SULFATE) 1MG

प्रशासन का मार्ग:

INTRAVENOUS

पैकेज में यूनिट:

5 ML DOSE X 5

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0108887007; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2001-07-26

उत्पाद विशेषताएं

                                _2014-07-03/131-pristine-eng-ventolin-IV-infusion-sol.doc _
_ _
_Page 1 of 22_
_ _
_ _
_ _
PRODUCT MONOGRAPH
PR
VENTOLIN
® I.V. INFUSION SOLUTION
salbutamol sulphate for injection
1000 mcg/mL
BP
Bronchodilator
(beta
2
-adrenergic agonist)
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
July 3, 2014
Submission Control No: 173386
_©_
_ 2014 GlaxoSmithKline Inc. All Rights Reserved _
_®_
_VENTOLIN is a registered trademark, used under license by
GlaxoSmithKline Inc. _
_2014-07-03/131-pristine-eng-ventolin-IV-infusion-sol.doc _
_ _
_Page 2 of 22_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACEUTI
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 03-07-2014

इस उत्पाद से संबंधित अलर्ट देखें